Key Insights• The United Arab Emirates biosurgery market represents one of the fastest-growing and most technologically advanced national markets for surgical biomaterials in the Middle East region. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The UAE biosurgery market is distinguished by its world-class healthcare infrastructure, high per capita healthcare expenditure, and the rapid adoption of advanced surgical technologies. Healthcare expenditure in the UAE reached approximately 5.4% of GDP in 2025, according to Ministry of Health and Prevention (MOHAP) figures. Health spending per capita stood at approximately $2,588 in 2025. The UAE ranks first globally in 10 healthcare competitiveness indicators in the IMD World Competitiveness Yearbook 2026, ahead of established health systems in Europe and East Asia. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and the country's strategic position as a regional hub for medical tourism and specialty care.• The UAE's aging population represents a growing demand driver.

As of 2025, 2.0% of the population (approximately 206,352 people) was aged 65 years or older, with this segment growing at 6.3% year-over-year. The regulatory environment is undergoing significant modernization. On January 2, 2025, the UAE dissolved MOHAP's device functions into a new Emirates Drug Establishment (EDE), which now serves as the sole federal authority governing medical device classification, market authorization, and post-market vigilance.• The market is seeing increasing participation from commercial reference laboratories serving both the companion animal and livestock sectors. Companion animals represent the largest revenue segment, while production animals are forecast to experience the fastest growth. Market Outlook• According to the research report, "UAE Biosurgery Market Overview, 2031 Overview, 2031," published by Actual Market Research, the UAE Biosurgery market is anticipated to grow at more than 7% CAGR from 2026 to 2031.• The UAE's healthcare expenditure continues to rise steadily, reaching an estimated 5.4% of GDP in 2025, according to MOHAP figures. Health spending per capita reached approximately $2,588 in 2025. The UAE ranks first globally in 10 healthcare competitiveness indicators in the IMD World Competitiveness Yearbook 2026, underscoring the country's commitment to healthcare excellence.

The aging UAE population represents a growing long-term demand driver. As of 2025, 2.0% of the population (approximately 206,352 people) was aged 65 years or older, with this segment growing at 6.3% year-over-year. Life expectancy in the UAE now stands at 78.7 years, up from 77.1 a decade ago.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. American Hospital Dubai has conducted more than 2,000 robot-assisted surgeries since 2020, with the facility aiming to reach around 1,000 cases per year by 2025. The UAE is rapidly becoming a regional hub for robotic and minimally invasive surgical techniques. Rising surgical volumes and expanding healthcare access are key drivers propelling market expansion.

Emirates Health Services (EHS) facilities alone performed 34,953 surgical procedures in 2025 across a wide range of specialties. The UAE attracted an estimated 930,000 medical tourists in 2025, generating more than AED 12 billion in direct healthcare revenue.Market DynamicsDriver: World-Class Healthcare Infrastructure and High Surgical VolumesThe UAE possesses one of the most advanced healthcare infrastructures globally, ranking first in 10 healthcare competitiveness indicators in the IMD World Competitiveness Yearbook 2026. Abu Dhabi alone has added more than 3,200 hospital beds since 2020 through expansions at Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, and the new Reem Island medical district. Dubai Health Authority (DHA) now oversees more than 4,200 licensed facilities in the emirate. The UAE employed more than 98,000 licensed healthcare professionals at the end of 2025, a 12% increase over the prior two years. Emirates Health Services (EHS) facilities performed 34,953 surgical procedures in 2025, reflecting the breadth and depth of surgical activity across the country.

The UAE also attracted an estimated 930,000 medical tourists in 2025, generating more than AED 12 billion in direct healthcare revenue.Challenge: Regulatory Transition and Workforce ConstraintsDespite the market's sophistication, biosurgery manufacturers face challenges from regulatory restructuring and workforce constraints. On January 2, 2025, the UAE dissolved MOHAP's device functions into the Emirates Drug Establishment (EDE), which now serves as the sole federal authority governing medical device classification, market authorization, import permits, and post-market vigilance. All medical device-related services previously overseen by MOHAP have been transferred to EDE, requiring companies to adapt to new submission processes and digital portals. While this centralization is designed to streamline processes, the transition period may create temporary uncertainty for manufacturers. Additionally, workforce constraints persist despite the UAE employing more than 98,000 licensed healthcare professionals, the rapid expansion of healthcare infrastructure requires continued investment in surgical workforce development.Trend: Accelerating Adoption of Robotic-Assisted and Minimally Invasive SurgeryThe UAE biosurgery market is experiencing a significant trend toward robotic-assisted and minimally invasive surgical techniques. American Hospital Dubai, one of the early adopters of robotic-assisted surgery in the region, has conducted more than 2,000 robot-assisted surgeries since 2020, averaging about 500 per year.

The facility continues to train more surgeons, aiming to reach around 1,000 cases by the end of 2025. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand. The UAE's regulatory modernization, including the creation of EDE and alignment with international frameworks such as EU MDR and FDA standards, further supports the adoption of innovative surgical technologies.Policies• The Emirates Drug Establishment (EDE) now serves as the sole federal authority for medical devices in the UAE, following the dissolution of MOHAP's device functions on January 2, 2025.• EDE's nine core regulatory services include classification of medical products, marketing authorization issuance and renewal, import permits, manufacturer licensing, advertising approvals, and post-market vigilance.• Medical devices are classified into four risk categories: Class I (low risk), Class II (medium risk), Class III (medium risk), and Class IV (high risk), with Class IV devices including heart valves, pacemakers, and implantable defibrillators.• Registration certificates are valid for 5 years. The approval timeline for medical device registration in the UAE is approximately 2 to 3 months (45 working days).• The Riayati unified health information exchange, operated by MOHAP, connects more than 2,800 facilities across all seven emirates for real-time patient record sharing at a national scale.• The UAE's regulatory framework aligns closely with international standards such as EU MDR and FDA, reflecting the country's commitment to regulatory harmonization and market predictability.Segment AnalysisUAE Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the UAE biosurgery market, driven by the high volume of orthopedic and spinal procedures. Emirates Health Services (EHS) facilities performed 3,384 orthopedic and spinal surgeries in 2025.

These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The UAE's growing elderly population and high incidence of sports-related injuries continue to drive demand for musculoskeletal interventions.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. With EHS facilities alone performing 34,953 surgical procedures in 2025, demand for hemostatic products is substantial and growing.• Surgical Sealants and Adhesives represent the fastest-growing product category in the UAE biosurgery market, driven by increasing adoption of robotic-assisted and minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The rapid expansion of robotic surgery, with American Hospital Dubai performing more than 2,000 robot-assisted surgeries since 2020, supports the growth of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries.

EHS facilities recorded 5,420 gynecology and obstetrics surgeries in 2025, the highest among all surgical specialties. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures. EHS facilities performed 5,299 general surgeries in 2025, reflecting the high volume of soft-tissue procedures.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines. EHS facilities recorded 3,503 gastrointestinal surgeries in 2025. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.UAE Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in the UAE, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures.

EHS facilities performed 3,384 orthopedic and spinal surgeries in 2025. The UAE's active lifestyle and growing elderly population continue to drive demand for musculoskeletal interventions.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures. EHS facilities recorded 5,299 general surgeries in 2025. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers.• Cardiovascular Surgery represents the fastest-growing application area in the UAE biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. EHS facilities performed 3,117 interventional cardiology procedures and 299 cardiac surgeries in 2025. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures.

EHS facilities recorded 466 neurological surgeries in 2025. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues. EHS facilities performed 1,021 plastic surgeries in 2025. The UAE's position as a regional hub for medical tourism and aesthetic procedures supports demand in this application.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system. EHS facilities recorded 5,420 gynecology and obstetrics surgeries in 2025, the highest among all surgical specialties. Products used include hemostatic agents, adhesion barriers, and surgical sealants.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system.

EHS facilities performed 1,098 urological surgeries in 2025. Products are used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS). EHS facilities recorded 150 thoracic surgeries in 2025. The rising burden of lung cancer and other thoracic conditions supports demand in this specialty.UAE Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the UAE biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The UAE's regulatory framework, aligned with international standards such as EU MDR and FDA, ensures high safety standards for biological materials.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the UAE market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life.

These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The UAE healthcare system's emphasis on efficiency and advanced technology favors synthetic alternatives for certain applications.UAE Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in the UAE, accounting for the majority of revenue. The UAE has 2.11 hospital beds per 1,000 people in 2025. Abu Dhabi has added more than 3,200 hospital beds since 2020. Dubai Health Authority oversees more than 4,200 licensed facilities. The concentration of complex surgical procedures makes hospitals the primary setting for biosurgical product utilization.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the UAE biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models.

The UAE has a growing network of day surgery centers, including Al Mazroui Medical Centre One Day Surgery in Abu Dhabi and Mediclinic Dubai Mall, Dubai's largest ambulatory care medical centre.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing. The UAE has numerous specialty clinics across all seven emirates.UAE Biosurgery Market Economics• The UAE biosurgery market benefits from a sophisticated public-private healthcare system, premium pricing, and strong medical tourism. Healthcare expenditure reached approximately 5.4% of GDP in 2025, with per-capita spending of around USD 2,588. The country attracted an estimated 930,000 medical tourists, generating more than AED 12 billion in healthcare revenue. Private hospitals play an important role in adopting advanced and premium biosurgical products.• The UAE has advanced healthcare infrastructure, with 2.11 hospital beds per 1,000 people and more than 4,200 licensed facilities under the Dubai Health Authority. The Riayati health information exchange connects over 2,800 facilities across all seven emirates.

More than 98,000 licensed healthcare professionals were employed in 2025, supporting increasing surgical capacity. Continued investment in hospital modernization and medical tourism will drive procedure volumes and biosurgery demand.• Innovation and technology adoption are major market drivers, particularly robotic-assisted and minimally invasive surgery. American Hospital Dubai has performed more than 2,000 robot-assisted surgeries since 2020, highlighting rapid adoption of advanced surgical technologies. The UAE is also attracting international investment and partnerships in robotic surgery and medical technology. Its strategic position as a regional healthcare hub further supports R&D, distribution, and commercialization opportunities for global biosurgery manufacturers.• The UAE biosurgery market is expected to maintain strong long-term growth, with more than 7% CAGR projected from 2026–2031. Regulatory modernization under the Emirates Drug Establishment (EDE), including alignment with international standards and approximately 2–3-month approval timelines, supports market access.

Rising life expectancy of 78.7 years, healthcare investment, medical tourism, and technology adoption will sustain demand. Manufacturers with strong provider partnerships and regulatory capabilities are well positioned to benefit.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.